Ritter Pharmaceuticals Inc (RTTR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ritter Pharmaceuticals Inc (RTTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8138
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ritter Pharmaceuticals Inc (Ritter) is a developer of therapeutic products for gastrointestinal diseases. The company’s lead product includes RP-G28, which is developed stimulate the growth of lactose-metabolizing bacteria in the colon to assist in digesting process. Its product is under the development for the treatment of lactose intolerance. The company conducts research and development for developing product, which is used for treating various therapeutic areas such as gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. Ritter is headquartered in Los Angeles, California, the US.

Ritter Pharmaceuticals Inc (RTTR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Ritter Pharma Raises US$5.4 Million In Venture Financing 10
Ritter Pharma Raises US$0.53 Million In Venture Financing 11
Partnerships 12
Ritter Pharma Enters into Agreement with University of British Columbia 12
Ritter Pharma Enters into Agreement with University of Nebraska 13
Equity Offering 14
Ritter Pharma Raises USD23 Million in Public Offering of Units 14
Ritter Pharma Files Registration Statement to Raise up to USD10 Million in Public Offering of Units 16
Ritter Pharma to Raise Funds through Public Offering of Shares 17
Ritter Pharma to Raise up to USD8.4 Million in Public offering of Shares 18
Ritter Pharma Raises USD3 Million in Private Placement of Shares 19
Ritter Pharma Raises USD5 Million in Public Offering of Shares 20
Ritter Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 21
Ritter Pharma Raises USD20 Million in IPO 22
Ritter Pharma Raises Funds through Third and Final Trache of Private Placement of Share and Warrants 24
Ritter Pharma Raises USD2.4 Million in Second Trache of Private Placement of Share and Warrants 25
Ritter Pharma Raises USD1 Million in First Trache of Private Placement of Share and Warrants 26
Ritter Pharmaceuticals Inc – Key Competitors 27
Ritter Pharmaceuticals Inc – Key Employees 28
Ritter Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 14, 2018: Ritter Pharmaceuticals reports financial results for the three and six months ended June 30, 2018 and recent progress 30
May 15, 2018: Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates 31
Mar 19, 2018: Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 32
Oct 31, 2017: Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 34
Aug 07, 2017: Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 35
May 09, 2017: Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates 36
Feb 27, 2017: Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 38
Corporate Communications 39
Feb 20, 2018: Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board 39
Oct 10, 2017: Ritter Pharmaceuticals Announces Management Change 40
Jan 17, 2017: Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ritter Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ritter Pharma Raises US$5.4 Million In Venture Financing 11
Ritter Pharma Raises US$0.53 Million In Venture Financing 12
Ritter Pharma Enters into Agreement with University of British Columbia 13
Ritter Pharma Enters into Agreement with University of Nebraska 14
Ritter Pharma Raises USD23 Million in Public Offering of Units 15
Ritter Pharma Files Registration Statement to Raise up to USD10 Million in Public Offering of Units 17
Ritter Pharma to Raise Funds through Public Offering of Shares 18
Ritter Pharma to Raise up to USD8.4 Million in Public offering of Shares 19
Ritter Pharma Raises USD3 Million in Private Placement of Shares 20
Ritter Pharma Raises USD5 Million in Public Offering of Shares 21
Ritter Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 22
Ritter Pharma Raises USD20 Million in IPO 23
Ritter Pharma Raises Funds through Third and Final Trache of Private Placement of Share and Warrants 25
Ritter Pharma Raises USD2.4 Million in Second Trache of Private Placement of Share and Warrants 26
Ritter Pharma Raises USD1 Million in First Trache of Private Placement of Share and Warrants 27
Ritter Pharmaceuticals Inc, Key Competitors 28
Ritter Pharmaceuticals Inc, Key Employees 29

List of Figures
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ritter Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Ritter Pharmaceuticals Inc (RTTR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acme United Corporation:企業の戦略・SWOT・財務情報
    Acme United Corporation - Strategy, SWOT and Corporate Finance Report Summary Acme United Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • InterOil Exploration & Production ASA (IOX):企業の財務・戦略的SWOT分析
    Summary InterOil Exploration & Production ASA (InterOil Exploration & Production) is an oil and gas company that provides petroleum exploration services. The company acquires, explores, develops and operates oil and natural gas properties, among others. It operates as an active license partner in se …
  • Rapid Pathogen Screening Inc-医療機器分野:企業M&A・提携分析
    Summary Rapid Pathogen Screening Inc (Rapid Pathogen) is a biotechnology company that designs, develops, manufactures and markets point-of-care diagnostic tests. The company uses its patented direct sampling micro-filtration and direct multi-planar chromafiltography technology to develop various tes …
  • HSN, Inc.:企業の戦略・SWOT・財務情報
    HSN, Inc. - Strategy, SWOT and Corporate Finance Report Summary HSN, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • NV Energy Inc:企業の戦略的SWOT分析
    NV Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • BrainStorm Cell Therapeutics Inc (BCLI):企業の財務・戦略的SWOT分析
    Summary BrainStorm Cell Therapeutics Inc (BrainStorm Cell Therapeutics) formerly Golden Hand Resources Inc is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy pl …
  • Companhia Energetica de Sao Paulo:発電所・企業SWOT分析
    Companhia Energetica de Sao Paulo - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Anglo American Plc:企業のM&A・事業提携・投資動向
    Anglo American Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anglo American Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • DCO Energy LLC-エネルギー分野:企業M&A・提携分析
    Summary DCO Energy LLC (DCO) is an energy development company that constructs, operates, develops, and maintains cogeneration and renewable energy projects across the US. The company's services include financing, performance testing, equipment and systems analyses, retro-commissioning services, ener …
  • National Company KazMunayGas:企業の戦略的SWOT分析
    National Company KazMunayGas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Tokuyama Corp (4043)
    Tokuyama Corp (4043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Koninklijke Wessanen N.V.:戦略・SWOT・企業財務分析
    Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Decas Cranberry Products, Inc.:企業の戦略・SWOT・財務情報
    Decas Cranberry Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Decas Cranberry Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hsh Nordbank Private Banking
    Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Mednax Inc (MD):医療機器:M&Aディール及び事業提携情報
    Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists compri …
  • CIMIC Group Limited:企業の戦略・SWOT・財務情報
    CIMIC Group Limited - Strategy, SWOT and Corporate Finance Report Summary CIMIC Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Taisei Corporation:企業の戦略・SWOT・財務分析
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Havila Shipping ASA (HAVI):石油・ガス:M&Aディール及び事業提携情報
    Summary Havila Shipping ASA (Havila) is a supplier of quality assured supply services to the international offshore industry. It owns and operates vessels and provides anchor handling, subsea construction, platform supply and multi-field rescue recovery services. The company’s fleet base includes an …
  • Daiichi Sankyo Co Ltd (4568):製薬・医療:M&Aディール及び事業提携情報
    Summary Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompa …
  • Patrick Industries Inc:企業のM&A・事業提携・投資動向
    Patrick Industries Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Patrick Industries Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆